Cipla Limited (CIPLA)
Press Release
Press Release - Q2FY27
- Consolidated revenue 7,404 Cr, -2% y-y; EBITDA 1,388 Cr (margin 18.7%, -630 bps y-y); PAT 878 Cr (-35% y-y)
- One-India business grew 12% y-y with branded prescription therapies leading
- North America revenue $172 Mn, up $10 Mn q-q; FDA approval for gAdvair Diskus
- South Africa private market grew 6.5%, outperforming market by 1.3x
- Emerging Markets & Europe revenue $101 Mn despite geopolitical challenges
- R&D spend 423 Cr (5.7% of sales); strong net cash 9,823 Cr
- MD Achin Gupta: focus on growth, productivity, and pipeline strength
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 CIPLA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add CIPLA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Cipla Limited
Important.
The summary above is generated automatically from Cipla Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.